Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43862   clinical trials with a EudraCT protocol, of which   7285   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-000482-31
    Sponsor's Protocol Code Number:MLN0002SC-3030
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2016-03-18
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-000482-31
    A.3Full title of the trial
    A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects with Ulcerative Colitis and Crohn?s Disease
    Estudio abierto, de fase IIIb para establecer la eficacia y la seguridad a largo plazo de vedolizumab subcutáneo en sujetos con colitis ulcerosa y enfermedad de Crohn
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Long-term effectiveness and Safety of Vedolizumab SC as a Therapy for Ulcerative Colitis and Crohn's Disease
    Este es un estudio de extensión abierto (OLE) de fase IIIb para comprender la seguridad y eficacia a largo plazo de vedolizumab subcutáneo (vedolizumab SC) en sujetos con colitis ulcerosa (CU) y enfermedad de Crohn (EC).
    A.3.2Name or abbreviated title of the trial where available
    Vedolizumab SC Long-Term Open-Label Extension Study
    Estudio de extensión abierto a largo plazo de vedolizumab SC
    A.4.1Sponsor's protocol code numberMLN0002SC-3030
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorTakeda Development Centre Europe, Ltd.
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportTakeda Development Center Americas, Inc
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationTakeda Development Centre Europe Ltd
    B.5.2Functional name of contact pointStudy Manager (Alonso Fernandez)
    B.5.3 Address:
    B.5.3.1Street AddressCalle Alsasua, 20
    B.5.3.2Town/ cityMadrid
    B.5.3.3Post code28023
    B.5.3.4CountrySpain
    B.5.4Telephone number0034 91 7149911
    B.5.6E-mailAlonso.Fernandez@takeda.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameVedolizumab SC
    D.3.2Product code MLN0002 SC
    D.3.4Pharmaceutical form Solution for injection in pre-filled syringe
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNVedolizumab SC
    D.3.9.1CAS number 943609-66-3
    D.3.9.2Current sponsor codeMLN0002 SC
    D.3.9.4EV Substance CodeSUB30452
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number108
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Ulcerative Colitis
    Crohn?s Disease
    Colitis Ulcerosa
    Enfermedad de Crohn
    E.1.1.1Medical condition in easily understood language
    Ulcerative Colitis
    Crohn?s Disease
    Colitis Ulcerosa
    Enfermedad de Crohn
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.1
    E.1.2Level PT
    E.1.2Classification code 10011401
    E.1.2Term Crohn's disease
    E.1.2System Organ Class 10017947 - Gastrointestinal disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.1
    E.1.2Level LLT
    E.1.2Classification code 10045365
    E.1.2Term Ulcerative colitis
    E.1.2System Organ Class 10017947 - Gastrointestinal disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    ? To obtain data on long term safety and tolerability of vedolizumab SC in Ulcerative Colitis (UC) and Crohn?s Disease (CD) subjects.
    Obtener datos a largo plazo de la seguridad y tolerabilidad de vedolizumab SC en sujetos con Colitis Ulcerosa y Enfermedad e Crohn
    E.2.2Secondary objectives of the trial
    ? To obtain data on adverse events of special interest (AESIs; serious infections including opportunistic infection such as PML, liver injury, malignancies, injection site reactions or systemic reactions and hypersensitivity) in UC and CD subjects receiving long-term vedolizumab SC treatment.
    ? To obtain data on maintaining clinical response and clinical remission in UC and CD subjects receiving long-term vedolizumab SC treatment.
    ? To obtain data on patient reported outcomes (PRO) in UC and CD subjects receiving long-term vedolizumab SC treatment.
    ? To obtain data on work productivity and activity impairment (WPAI-UC; WPAI-CD) in UC and CD subjects receiving long-term vedolizumab SC treatment.
    ? To obtain data on time to major UC and CD-related events (hospitalizations, bowel surgeries,
    and procedures) in UC and CD subjects receiving long-term vedolizumab SC treatment.
    Obtener datos:
    -Acontecimientos adversos de especial interés (AAEI; infecciones graves incluidas infecciones oportunistas como LMP, lesión hepática, neoplasias malignas, reacciones en el lugar de la inyección o reacciones sistémicas y de hipersensibilidad) en sujetos con CU y EC que reciban tratamiento a largo plazo con vedolizumab SC.
    -Mantenimiento de la respuesta clínica y la remisión clínica en sujetos con CU y EC que reciban tratamiento con vedolizumab SC a largo plazo
    -Resultados comunicados por los pacientes (RCP) en sujetos con CU y EC que reciban tratamiento con vedolizumab SC a largo plazo
    -Productividad laboral y el deterioro de la actividad (WPAI-CU; WPAI-EC) en sujetos con CU y EC que reciban tratamiento a largo plazo con vedolizumab SC
    -Tiempo hasta la aparición de acontecimientos importantes relacionados con la CU y EC (hospitalizaciones, cirugías intestinales y procedimientos) en sujetos con CU y EC que reciban tratamiento a largo plazo con vedolizumab SC
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. The subject has previously participated in Study MLN0002SC-3027 or MLN0002SC-3031, and, in the opinion of the investigator, tolerated the study drug well. Subjects who withdraw early from Study MLN0002SC-3027 or MLN0002SC-3031 must have withdrawn due to treatment failure (ie, as determined by disease worsening or need for rescue medications from Week 14) during the Maintenance Period.
    2. Subjects with a family history of colorectal cancer, personal history of increased colorectal cancer risk, age >50 years, or other known risk factor must be up-to-date on colorectal cancer surveillance.
    3. Subjects with extensive colitis or pancolitis of >8 years duration or left-sided colitis of >12 years duration must have documented evidence that a surveillance colonoscopy was performed within 12 months of the initial Screening Visit of MLN0002SC-3027 or MLN0002SC-3031.
    4. May be receiving a therapeutic dose of the following drugs provided that the dose has been stable throughout the qualifying double-blind study:
    ? Oral 5-ASA compounds.
    ? Oral corticosteroid therapy (prednisone or equivalent steroid at a dose ?30 mg/day, budesonide at a dose ?9 mg/day).
    ? Topical (rectal) treatment with 5-ASA or corticosteroid enemas/suppositories.
    ? Probiotics (eg, Culturelle, Saccharomyces boulardii).
    ? Antidiarrheals (eg, loperamide, diphenoxylate with atropine) for control of chronic diarrhea.
    ? Antibiotics used for treatment of IBD (ie, ciprofloxacin, metronidazole).
    ? Azathioprine or 6-mercaptopurine, provided the patient was receiving this medication during prior participation in Study MLN002SC-3027.
    ? Methotrexate, provided the patient was receiving this medication during prior participation
    in Study MLN002SC-3031.
    -El sujeto ha participado previamente en el estudio MLN0002SC-3027 o MLN0002SC-3031 y, en la opinión del investigador, toleró bien el fármaco del estudio. Durante el periodo de mantenimiento, los sujetos que se retiraron de forma temprana del estudio MLN0002SC-3027 o MLN0002SC-3031 deben de haberlo hecho debido a un fracaso en el tratamiento (es decir, determinado por el empeoramiento de la enfermedad o la necesidad de medicamentos de rescate desde la semana 14 del estudio en cuestión).
    -Los sujetos con antecedentes familiares de cáncer colorrectal, antecedentes personales de aumento del riesgo de cáncer colorrectal, mayores de 50 años o con otros factores de riesgo conocidos deben llevar una vigilancia actualizada de estos factores de riesgo de cáncer colorrectal.
    -El sujeto con colitis extensa o pancolitis > 8 años de duración o colitis del lado izquierdo > 12 años de duración deberá tener indicios documentados de que se ha realizado una colonoscopia de vigilancia durante los 12 meses previos a la visita de selección inicial de MLN0002SC-3027 o MLN0002SC-3031.
    -9. Puede estar recibiendo una dosis terapéutica de los siguientes fármacos siempre que la dosis se haya mantenido estable a lo largo del estudio apto de doble ciego:
    • Compuestos de 5-ASA oral.
    • Tratamiento oral con corticosteroides (prednisona o esteroide equivalente a dosis de ≤ 30 mg/día, budesonida a dosis de ≤ 9 mg/día).
    • Tratamiento tópico (rectal) con 5-ASA o supositorios/enemas de corticosteroides.
    • Probióticos (p. ej., Culturelle, Saccharomyces boulardii).
    • Antidiarreicos (p. ej., loperamida, difenoxilato con atropina) para el control de la diarrea crónica.
    • Antibióticos usados para el tratamiento de la EII (es decir, ciprofloxacina, metronidazola).
    • Azatioprina o 6-mercaptopurina, siempre que el paciente estuviera recibiendo esta medicación antes de la participación en el estudio MLN002SC-3027.
    • Metotrexato, siempre que el paciente estuviera recibiendo esta medicación antes de la participación en el estudio MLN002SC-3031.
    E.4Principal exclusion criteria
    1. The subject required surgical intervention for IBD during or after participation in Study MLN0002SC-3027 or MLN0002SC-3031, currently requires surgical intervention for IBD, or is anticipated to require surgical intervention for IBD during this study.
    2. The subject has had previous exposure to approved or investigational anti-intergins (eg, natalizumab, efalizumab, etrolizumab, AMG 181) or anti-MAdCAM1 antibodies or rituximab.
    3. The subject has had hypersensitivity to any of the vedolizumab excipients.
    4. Any live vaccinations within 30 days prior to vedolizumab SC administration.
    5. The subject has developed a chronic or severe infection, or, any new, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immunological, endocrine/metabolic, neurologic, oncologic, or other medical disorder during or after participation in a prior vedolizumab study that, in the opinion of the investigator, would confound the study results or compromise subject safety.
    6. The subject has withdrawn from Study MLN0002SC-3027 or MLN0002SC-3031due to a study-drug related AE.
    7. The subject is unwilling or unable to self inject, or does not have a caregiver (defined as a legal adult) to inject the study medication.
    8. The subject has any history of malignancy, except for the following: (a) adequately treated nonmetastatic basal cell skin cancer; (b) squamous cell skin cancer that has been adequately treated and that has not recurred for at least 1 year prior to enrollment; and (c) history of cervical carcinoma in situ that has been adequately treated and that has not recurred for at least 3 years prior to enrollment. Subjects with remote history of malignancy (eg, >10 years since completion of curative therapy without recurrence) will be considered based on the nature of the malignancy and the therapy received and must be discussed with the sponsor on a case-by-case basis prior to enrollment.
    9. The subject has a history of any major neurological disorders, including stroke, multiple sclerosis, brain tumor, or demylinating neurodegenerative disease.
    10. The subject has a positive PML subjective symptom checklist prior to the administration of study drug.
    1. El sujeto ha necesitado intervención quirúrgica para EII durante o tras la participación en el estudio MLN0002SC-3027 o MLN0002SC-3031, actualmente necesita intervención quirúrgica para EII, o se prevé que necesitará intervención quirúrgica para EII durante este estudio.
    2. El sujeto había estado expuesto anteriormente a antiintegrinas aprobadas o en investigación (p. ej., natalizumab, efalizumab, etrolizumab, AMG 181) o anticuerpos anti-MAdCAM1 o rituximab.
    3. El sujeto había tenido hipersensibilidad a cualquier excipiente de vedolizumab.
    5. El sujeto ha desarrollado una infección crónica o grave, o cualquier trastorno nuevo inestable o incontrolado de tipo cardiovascular, pulmonar, hepático, renal, GI, genitourinario, hematológico, de coagulación, inmunológico, endocrino/metabólico, neurológico, oncológico u otro tipo de trastorno médico durante o después de la participación en un estudio previo con vedolizumab que, en opinión del investigador, podría confundir los resultados del estudio y comprometer la seguridad del sujeto.
    6. El sujeto se ha retirado del estudio MLN0002SC-3027 o MLN0002SC-3031 debido a un AA relacionado con el fármaco de estudio.
    7. El sujeto no quiere o no puede autoinyectarse, o no tiene un cuidador (definido como un adulto legal) que le inyecte el fármaco del estudio.
    8. El sujeto tiene antecedentes de neoplasia maligna, excepto los siguientes casos: (a) cáncer de piel basocelular no metastásico adecuadamente tratado, (b) cáncer de piel de células escamosas adecuadamente tratado y que no ha presentado recurrencia durante al menos un año antes de la selección; y (c) antecedentes de carcinoma de cuello uterino in situ adecuadamente tratado y que no ha presentado recurrencia durante al menos los 3 años previos a la selección. Se considerará a los sujetos con antecedentes remotos de neoplasia maligna (p. ej., > 10 años desde la finalización del tratamiento curativo sin recurrencia) en función de la naturaleza de la neoplasia maligna y del tratamiento recibido y deberá discutirse con el promotor caso por caso antes de la inscripción.
    9. El sujeto presenta antecedentes de cualquier trastorno neurológico importante, como accidente cerebrovascular, esclerosis múltiple, tumor cerebral, enfermedad desmielinizante neurodegenerativa.
    10. El sujeto presenta una lista de verificación de síntomas subjetivos de la LMP positiva previa a la administración del fármaco del estudio.
    E.5 End points
    E.5.1Primary end point(s)
    ? Subject year adjusted treatment emergent-related AEs and SAEs during long-term vedolizumab SC treatment.
    • AA y AAG relacionados con la emergencia del tratamiento ajustado por año-sujeto durante el tratamiento con vedolizumab SC a largo plazo.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Collection of AEs will commence from the time that the subject is first administered study medication (Week 0). Routine collection of AEs will continue until 18 weeks post last dose of medication.

    AE/SAE assessments:
    QW: Weeks 0, 1, 2, 3, 4, 5, 6, 7, 8, 16 then every 8 weeks, plus unscheduled and final safety/early termination visit.
    Q2W: Weeks 0, 2, 4, 6, 8, 16 then every 8 weeks, plus unscheduled and final safety/early termination visit.
    Colección de AA que se iniciará desde el momento en que el sujeto se le administra la primera medicación del estudio (semana 0). Recolección rutinaria de AA que continuará hasta las 18 semanas después de la última dosis del medicamento.
    Evaluaciones AA/ AAG:
    QW: semanas 0, 1, 2, 3, 4, 5, 6, 7, 8, 16 y luego cada 8 semanas, más visitas no programadas y de seguridad/terminación temprana.
    Q2W: las semanas 0, 2, 4, 6, 8, 16 y luego cada 8 semanas, más visitas no programadas y de seguridad/terminación temprana.
    E.5.2Secondary end point(s)
    ? Subject year adjusted AESIs during long-term vedolizumab SC treatment.
    ? Proportion of subjects with clinical response during long-term vedolizumab SC treatment using partial Mayo scores in UC subjects and Harvey-Bradshaw Index (HBI) scores in CD subjects.
    ? Proportion of subjects with clinical remission during long-term vedolizumab SC treatment using partial Mayo scores in UC subjects and Harvey-Bradshaw Index (HBI) scores in CD subjects.
    • AAEI ajustados por año-sujeto durante el tratamiento con vedolizumab SC a largo plazo.
    • Proporción de sujetos con respuesta clínica durante el tratamiento a largo plazo con vedolizumab SC usando las puntuaciones parciales de Mayo en sujetos con CU y las puntuaciones del índice de Harvey-Bradshaw (IHB) en sujetos con EC.
    • Proporción de sujetos con remisión clínica durante el tratamiento con vedolizumab SC usando las puntuaciones parciales de Mayo en sujetos con CU y las puntuaciones del índice de Harvey-Bradshaw (IHB) en sujetos con EC.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Collection of AEs will commence from the time that the subject is first administered study medication (Week 0). Routine collection of AEs will continue until 18 weeks post last dose of medication.

    AE/SAE assessments:
    QW: Weeks 0, 1, 2, 3, 4, 5, 6, 7, 8, 16 then every 8 weeks, plus unscheduled and final safety/early termination visit.
    Q2W: Weeks 0, 2, 4, 6, 8, 16 then every 8 weeks, plus unscheduled and final safety/early termination visit.

    Disease activity (Mayo/HBI):
    QW and Q2W: Weeks 0, 4, 8, 16 then every 8 weeks, plus unscheduled and final safety/early termination visit.
    Colección de AA que se iniciará desde el momento en que el sujeto se le administra la primera medicación del estudio (semana 0). Recolección rutinaria de AA que continuará hasta las 18 semanas después de la última dosis del medicamento.
    Evaluaciones AA/ AAG:
    QW: semanas 0, 1, 2, 3, 4, 5, 6, 7, 8, 16 y luego cada 8 semanas, más visitas no programadas y de seguridad/terminación temprana.
    Q2W: las semanas 0, 2, 4, 6, 8, 16 y luego cada 8 semanas, más visitas no programadas y de seguridad/terminación temprana.

    Actividad de la enfermedad (Mayo/HBI):
    QW and Q2W: Semanas 0, 4, 8, 16 y luego cada 8 semanas, más visitas no programadas y de seguridad/terminación temprana.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Information not present in EudraCT
    E.8.2.2Placebo Information not present in EudraCT
    E.8.2.3Other Information not present in EudraCT
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned7
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA112
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Belgium
    Bosnia and Herzegovina
    Brazil
    Bulgaria
    Canada
    Chile
    Croatia
    Czech Republic
    Denmark
    Estonia
    France
    Germany
    Hungary
    Israel
    Italy
    Japan
    Korea, Republic of
    Lithuania
    Mexico
    Netherlands
    Poland
    Romania
    Russian Federation
    Serbia
    Slovakia
    Spain
    Sweden
    Turkey
    Ukraine
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Subjects enrolled onto the study will be eligible to continue receiving vedolizumab SC until the vedolizumab SC formulation becomes commercially available in their country of residence, the subject withdraws from the study, or the sponsor decides to close the study.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months5
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 659
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 33
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state19
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 259
    F.4.2.2In the whole clinical trial 692
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The study medication will not be available upon discontinuation of the subject's participation in the study. The subject should be returned to the care of a physician and standard therapies as required.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-05-29
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-05-20
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 26 15:03:25 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA